Accretion Pharmaceuticals IPO
Amaan Khan | May , 2025
Accretion Pharmaceuticals, a Gujarat-based pharmaceutical company, has opened its Initial Public Offering (IPO) for subscription from May 14 to May 16, 2025. The company aims to raise ₹29.75 crore through a fresh issue of 29.46 lakh equity shares. The IPO follows a book-building process and will be listed on the NSE SME platform on May 21, 2025.
Key Details:
Price Band: ₹96 to ₹101 per share
Lot Size: 1,200 shares (minimum investment of ₹1,21,200)
Issue Type: Book Built Issue
Listing Date: May 21, 2025
Registrar: Kfin Technologies
Lead Manager: Jawa Capital Service
Financial Performance:
In FY24, Accretion Pharmaceuticals reported a revenue of ₹33.93 crore, up from ₹29.53 crore in FY23. The profit after tax (PAT) surged to ₹3.87 crore in FY24 from ₹10.39 lakh in the previous fiscal year.
Use of Proceeds:
The company plans to utilize the IPO proceeds for multiple purposes, including capital expenditure towards purchasing new equipment and upgrading its existing manufacturing facility. Part of the funds will also be used for repaying certain borrowings, funding working capital requirements, and meeting general corporate expenses.
Accretion Pharmaceuticals IPO Market Lot
The Accretion Pharmaceuticals IPO minimum market lot is 1200 shares with ₹1,21,200 application amount.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1200 | ₹1,21,200 |
| Retail Maximum | 1 | 1200 | ₹1,21,200 |
| S-HNI Minimum | 2 | 2,400 | ₹2,42,400 |
Accretion Pharmaceuticals IPO Details
| IPO Open Date: | 14-May-25 |
|---|---|
| IPO Close Date: | 16-May-25 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹96 to ₹101 Per Share |
| Issue Size: | Approx ₹29.75 Crores |
| Fresh Issue: | Approx ₹29.75 Crores |
| Issue Type: | Book Built Issue |
| IPO Listing: | NSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Accretion Pharmaceuticals IPO Valuation – FY2024 (KPI)
Check Accretion Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
|---|---|
| ROE: | 72.80% |
| ROCE: | 36.73% |
| EBITDA Margin: | 23.06% |
| PAT Margin: | 11.51% |
| Debt to equity ratio: | 2.52 |
| Earning Per Share (EPS): | ₹9.69 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 72.47% |
| Net Asset Value (NAV): | ₹- |
Accretion Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹33.94 crores in 2024 against ₹29.53 crore in 2023. The company reported profit of ₹3.88 crores in 2024 against profit of ₹0.10 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2022 | ₹22.58 | ₹783.90 | ₹0.08 | ₹17.74 |
| 2023 | ₹29.53 | ₹1472.25 | ₹0.10 | ₹20.58 |
| 2024 | ₹33.94 | ₹2883.26 | ₹3.88 | ₹27.05 |
| Jul-24 | ₹11.89 | ₹1423.72 | ₹1.57 | ₹29.34 |
Accretion Pharmaceuticals IPO Dates
The Accretion Pharmaceuticals IPO date is May 14 and the close date is May 16. The Accretion Pharmaceuticals IPO allotment will be finalized on May 19 and the IPO listing on May 21.
| IPO Open Date: | 14-May-25 |
|---|---|
| IPO Close Date: | 16-May-25 |
| Basis of Allotment: | 19-May-25 |
| Refunds: | 20-May-25 |
| Credit to Demat Account: | 20-May-25 |
| IPO Listing Date: | 21-May-25 |
Promoters of Accretion Pharmaceuticals IPO
The promoters of the company are Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel and Mr. Hardik Mukundbhai Prajapati.
About Accretion Pharmaceuticals IPO
Established in 2012, Accretion Pharmaceuticals Limited has emerged as a prominent player in the pharmaceutical industry, specializing in the manufacturing and marketing of a diverse range of healthcare products. Their product portfolio includes tablets, capsules, oral liquids, external preparations such as ointments and creams, and oral powders. Beyond producing their own branded products, Accretion also offers contract manufacturing services, catering to various pharmaceutical entities through licensing agreements
The company’s state-of-the-art manufacturing facility is located in Sanand, Ahmedabad, Gujarat, encompassing a 65,000 sq. ft. area. This facility is equipped with modern machinery and adheres to stringent quality standards, holding certifications like WHO-cGMP, GLP, ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 . Such certifications underscore Accretion’s commitment to quality assurance, environmental sustainability, and food safety management.
Accretion Pharmaceuticals has established a significant global presence, exporting its products to over 30 countries across Africa, Southeast Asia, and the Middle East . This international footprint reflects the company’s dedication to expanding its reach and delivering quality healthcare solutions worldwide.2025, the company employs a team of over 200 professionals, including four Executive Directors . This skilled workforce plays a crucial role in driving Accretion’s growth and maintaining its reputation for excellence in the pharmaceutical sector
Peer Group Comparison Accretion Pharmaceuticals
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Sakar Healthcare Limited | 5.64 | 65.3 | 4.45% | 120.65 | – Cr. |
| Lincoln Pharmaceuticals Limited | 46.58 | 12.58 | 15.74% | 295.98 | – Cr. |
| Sotac Pharmaceuticals Limited | 5.24 | 23.09 | 11.91% | 43.69 | – Cr. |
Objects of IPO
- Capital expenditure towards purchase of new equipment/ machineries, etc.
- Capital expenditure towards upgradation of existing manufacturing facility
- Repayment/prepayme nt of certain borrowings availed by the Company
- Funding working capital requirements
- General Corporate Purpose
IPO Lead Managers aka Merchant Bankers
- Jawa Capital Services Private Limited
Company Address
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
Check Grey market premium at below
(GMP)
Accretion Pharmaceuticals IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: apl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/